241993 Introduction: The pivotal global phase 3 ZIRCON study has demonstrated that [89
Zr] Zirconium-DFO-girentuximab (89 Zr-TLX250) PET/CT is highly accurate and well …

P257 Introduction: Carbonic Anhydrase IX is a cell-surface transmembrane metalloenzyme
involved in acid-base balance and a tumor-associated antigen that is over-expressed in …

P1113 Introduction: The increasing detection of renal masses presents a significant patient
management challenge. Diagnostic options include conventional imaging, which cannot …

4554 Background: Conventional tools (eg, CT, MRI, biopsy) have limitations for
characterizing renal mass histology; approx. 25% of patients with an indeterminant renal …

LBA602 Background: The increasing detection of renal masses presents a significant patient
management challenge. Diagnostic options include cross-sectional imaging, which cannot …

Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell
carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the …

Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer
drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of …

Summary 89 Zr-girentuximab PET/CT has the ability to diagnose ccRCC in localized
disease. In metastatic disease, it enables the differentiation of ccRCC from non-ccRCC …

Background PET/CT imaging with Zirconium-89 labeled [89Zr] Zr-DFO-girentuximab, which
targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell …

Purpose In this phase I study, we evaluated the safety, biodistribution and dosimetry of [89
Zr] Zr-DFO-girentuximab (89 Zr-girentuximab) PET/CT imaging in patients with suspicion of …